You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company expects to use its centrifugal microfluidic platform to launch a dengue assay early in 2018 and a Zika-dengue assay later in 2018.
The Bay Area firm is planning to launch a low-cost, microfluidics-based infectious disease diagnostic called the Simple Chip in the next few years.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
The company has built a small and rugged system boasting 20-minute qPCR reactions and plans to expand the platform for other types of diagnostics.
